Laurent Thomas, Simeone Jason, Kuwatsuru Ryohei, Hirano Takahiro, Graham Sophie, Wakabayashi Ryozo, Phillips Robert, Isomura Tatsuya
Clinical Study Support Inc., 2F Daiei Bldg., 1-11-20 Nishiki, Naka-ku, Nagoya, 460-0003, Japan.
Fifth Floor, Real-World Evidence, Evidera, 500 Totten Pond Road, Waltham, MA, 02451, USA.
Drugs Real World Outcomes. 2022 Jun;9(2):175-187. doi: 10.1007/s40801-022-00296-5. Epub 2022 Mar 18.
In Japan, an increasing interest in real-world evidence for hypothesis generation and decision-making has emerged in order to overcome limitations and restrictions of clinical trials. We sought to characterize the context and concrete considerations of when to use Medical Data Vision (MDV) and JMDC databases, the main Japanese real-world data (RWD) sources accessible by pharmaceutical companies. Use cases for these databases, and related issues and considerations, were identified and summarized based on a literature search and experience-based knowledge. Studies conducted using MDV or JMDC were mostly descriptive in nature, or explored potential risk factors by evaluating associations with a target outcome. Considerations such as variable ascertainment at different time points, including issues relating to treatment identification and missing data, were highlighted for these two databases. Although several issues were commonly shared (e.g., only month of event occurrence reported), some database-specific issues were also identified and need to be accounted for. In conclusion, MDV and JMDC present limitations that are relatively typical of RWD sources, though some of them are unique to Japan, such as the identification of event occurrence and the inability to track patients visiting different healthcare settings. Addressing study design and careful result interpretation with respect to the specificities and uniqueness of the Japanese healthcare system is of particular importance. This aspect is especially relevant with respect to the growing global interest of conducting RWD studies in Japan.
在日本,为克服临床试验的局限性和限制,人们对用于假设生成和决策的真实世界证据的兴趣日益浓厚。我们试图描述使用医学数据愿景(MDV)和JMDC数据库(制药公司可获取的主要日本真实世界数据(RWD)来源)的背景及具体考量因素。基于文献检索和经验知识,确定并总结了这些数据库的用例以及相关问题和考量因素。使用MDV或JMDC进行的研究大多本质上是描述性的,或者通过评估与目标结局的关联来探索潜在风险因素。针对这两个数据库,强调了不同时间点的变量确定等考量因素,包括与治疗识别和缺失数据相关的问题。尽管存在一些共同问题(例如,仅报告事件发生月份),但也识别出了一些特定于数据库的问题,需要加以考虑。总之,MDV和JMDC存在相对典型的RWD来源的局限性,尽管其中一些是日本特有的,例如事件发生的识别以及无法跟踪就诊于不同医疗机构的患者。针对日本医疗系统的特殊性和独特性进行研究设计并谨慎解释结果尤为重要。这一点在全球对在日本开展RWD研究的兴趣日益浓厚的背景下尤为相关。